Benralizumab for Adolescent Patients with Severe, Eosinophilic Asthma: Safety and Efficacy after Three Years of Treatment.

[1]  H. Makita,et al.  Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. , 2019, The Lancet. Respiratory medicine.

[2]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[3]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[4]  N. Kenyon,et al.  Benralizumab: a unique IL-5 inhibitor for severe asthma , 2016, Journal of asthma and allergy.

[5]  K. Ranade,et al.  Reductions in eosinophil biomarkers by benralizumab in patients with asthma. , 2016, Respiratory Medicine.

[6]  David Price,et al.  Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice , 2016, Journal of asthma and allergy.

[7]  P. Paggiaro,et al.  Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study , 2015, BMJ Open.

[8]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[9]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.